Pentoxifylline alleviates hypertension in metabolic syndrome: effect on low-grade inflammation and angiotensin system
- PMID: 25412944
- DOI: 10.1007/s40618-014-0209-z
Pentoxifylline alleviates hypertension in metabolic syndrome: effect on low-grade inflammation and angiotensin system
Abstract
Introduction and objective: Pentoxifylline is a well-tolerated drug used in treatment of vascular insufficiency. We previously showed that pentoxifylline protects from impairment in vascular reactivity in cases of metabolic syndrome. The aim of this study was to investigate the protective effect of pentoxifylline against hypertension in metabolic syndrome rats.
Methods: Metabolic syndrome was induced by feeding rats a high-fructose, high-fat and high-salt diet for 12 weeks. Pentoxifylline was administered daily (30 mg kg(-1)) during the last 4 weeks of the study, before blood pressure parameters were assessed at the end of study. In addition, serum levels of glucose, fructosamine, insulin, tumor necrosis factor alpha, adiponectin, and lipid profile parameters were determined. Aortic protein levels of angiotensin II and angiotensin receptor 1 were assessed by immunofluorescence.
Results: Pentoxifylline administration prevented excessive weight gain but did not affect hyperinsulinemia or hypertriglyceridemia seen in metabolic syndrome animals. In addition, pentoxifylline prevented the elevations in mean blood pressure associated with metabolic syndrome. Particularly, pentoxifylline prevented elevations in systolic, diastolic, and notch blood pressure; however, elevation in pulse blood pressure was not affected. Further, pentoxifylline alleviated the low-grade inflammation associated with metabolic syndrome, as reflected by the significantly lower serum tumor necrosis factor α and higher serum adiponectin levels metabolic syndrome animals treated with pentoxifylline. Also, pentoxifylline inhibited elevated expression of angiotensin receptor 1 in aortic tissue of metabolic syndrome animals.
Conclusion: Pentoxifylline directly alleviated hypertension in metabolic syndrome rats, at least in part, via amelioration of low-grade inflammation and inhibition of angiotensin system.
Keywords: Hypertension; Insulin resistance; Pentoxifylline; Vascular.
Similar articles
-
Pentoxifylline alleviates cardiac ischemia and dysfunction following experimental angina in insulin resistance.PLoS One. 2014 May 29;9(5):e98281. doi: 10.1371/journal.pone.0098281. eCollection 2014. PLoS One. 2014. PMID: 24874295 Free PMC article.
-
Xanthine oxidase inhibition alleviates the cardiac complications of insulin resistance: effect on low grade inflammation and the angiotensin system.J Transl Med. 2015 Mar 6;13:82. doi: 10.1186/s12967-015-0445-9. J Transl Med. 2015. PMID: 25889404 Free PMC article.
-
Pentoxifylline alleviates vascular impairment in insulin resistance via TNF-α inhibition.Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):277-85. doi: 10.1007/s00210-011-0669-z. Epub 2011 Jul 29. Naunyn Schmiedebergs Arch Pharmacol. 2011. PMID: 21800096
-
High fructose consumption combined with low dietary magnesium intake may increase the incidence of the metabolic syndrome by inducing inflammation.Magnes Res. 2006 Dec;19(4):237-43. Magnes Res. 2006. PMID: 17402291 Review.
-
[Hypertension].Nihon Rinsho. 2004 Jun;62(6):1104-7. Nihon Rinsho. 2004. PMID: 15206148 Review. Japanese.
Cited by
-
Zingerone alleviates the delayed ventricular repolarization and AV conduction in diabetes: Effect on cardiac fibrosis and inflammation.PLoS One. 2017 Dec 5;12(12):e0189074. doi: 10.1371/journal.pone.0189074. eCollection 2017. PLoS One. 2017. PMID: 29206854 Free PMC article.
-
Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study.Int Immunopharmacol. 2021 Jan;90:107209. doi: 10.1016/j.intimp.2020.107209. Epub 2020 Nov 26. Int Immunopharmacol. 2021. PMID: 33278747 Free PMC article. Clinical Trial.
-
Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.Med Hypotheses. 2020 Nov;144:109988. doi: 10.1016/j.mehy.2020.109988. Epub 2020 Jun 9. Med Hypotheses. 2020. PMID: 32540603 Free PMC article.
-
A Nano-Pharmaceutical Formula of Quercetin Protects from Cardiovascular Complications Associated with Metabolic Syndrome.Front Pharmacol. 2021 Aug 11;12:696981. doi: 10.3389/fphar.2021.696981. eCollection 2021. Front Pharmacol. 2021. PMID: 34456723 Free PMC article.
-
Blood-borne interleukin-1β acts on the subfornical organ to upregulate the sympathoexcitatory milieu of the hypothalamic paraventricular nucleus.Am J Physiol Regul Integr Comp Physiol. 2018 Mar 1;314(3):R447-R458. doi: 10.1152/ajpregu.00211.2017. Epub 2017 Nov 22. Am J Physiol Regul Integr Comp Physiol. 2018. PMID: 29167166 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical